61 completed, 10 unknown, 9 terminated, 8 not yet recruiting. 100 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 100 | Completed 61, Unknown 10, Terminated 9, Not yet recruiting 8, Recruiting 6, Active not recruiting 3, Withdrawn 3 |
Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis | Phase 4 | Not yet recruiting | Boston Children's Hospital | 100 | 2031-01-01 | 2026-03-10 |
| Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis | Phase 4 | Not yet recruiting | Wake Forest University Health Sciences | 50 | 2026-12-01 | 2026-09-04 |
| AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis | Phase 4 | Not yet recruiting | Forefront Dermatology S.C | 250 | 2026-11-11 | 2026-10-02 |
| A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis Dupilumab - Atopic Dermatitis | Phase 4 | Not yet recruiting | Sanofi | 56 | 2026-10-28 | 2026-10-29 |
| Abrocitinib Dose Tapering in Patients With Atopic Dermatitis Abrocitinib - Atopic Dermatitis | Phase 4 | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2026-10-01 | 2026-09-29 |
| The Impact of Dietary Salt on the Severity of Eczema Sodium chloride tablets, Placebo Tablets - Eczema, Atopic Dermatitis | Phase 4 | Recruiting | University of California, San Francisco | 40 | 2026-08-10 | 2026-09-10 |
| Azithromycin in Atopic Dermatitis Betamethasone or tacrolimus ointments, Azithromycin - Atopic Dermatitis | Phase 4 | Not yet recruiting | Cairo University | 40 | 2026-08-01 | 2026-07-20 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. Roflumilast Cream 0.15% - ITCH, Atopic Dermatitis | Phase 4 | Recruiting | Integrative Skin Science and Research | 40 | 2026-07-21 | 2026-08-13 |
| Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis Crisaborole 2% Topical Application Ointment [EUCRISA, tacrolimus 0.1% - Atopic Dermatitis | Phase 4 | Not yet recruiting | Hayat Abad Medical Complex, Peshawar | 148 | 2026-03-01 | 2026-03-02 |
| Lebrikizumab in Moderate-to-severe Atopic Dermatitis lebrikizumab - Atopic Dermatitis | Phase 4 | Active not recruiting | Johann E Gudjonsson MD PhD | 48 | 2025-07-02 | 2026-09-15 |
| A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden Lebrikizumab - Atopic Dermatitis | Phase 4 | Completed | Eli Lilly and Company | 233 | 2025-06-16 | 2026-10-15 |
| Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients Dupilumab, Tofacitinib - Atopic Dermatitis | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 220 | 2025-01-01 | 2024-06-20 |
| Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis Dupilumab - Atopic Dermatitis, Sleep Disturbance | Phase 4 | Recruiting | Northwestern University | 40 | 2024-08-12 | 2026-04-27 |
| Dupilumab De-escalation in Pediatric Atopic Dermatitis Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose - Atopic Dermatitis | Phase 4 | Terminated | Johns Hopkins University | 1 | 2024-04-01 | 2026-11-03 |
| Bodewell Products for the Treatment of Atopic Dermatitis Bodewell Calming Cream - Atopic Dermatitis | Phase 4 | Active not recruiting | University of Alabama at Birmingham | 15 | 2023-11-01 | 2026-03-02 |
| Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Second-line systemic treatment, Folllow-up of second-line systemic treatment already started - Atopic Dermatitis | Phase 4 | Unknown | Instituto de Investigación Hospital Universitario La Paz | 150 | 2023-09-25 | 2024-04-16 |
| Tralokinumab for Dupilumab Failures tralokinumab - Atopic Dermatitis | Phase 4 | Terminated | Psoriasis Treatment Center of Central New Jersey | 7 | 2023-09-11 | 2026-05-22 |
| DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema Dupilumab - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 4 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 216 | 2023-08-14 | 2026-10-29 |
| A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis Upadacitinib - Atopic Dermatitis | Phase 4 | Completed | AbbVie | 461 | 2023-05-29 | 2025-07-29 |
Showing 20 of 100. Sign in to see all of them.
Dermatitis, Atopic (100) · Eczema (20) · Pruritus (6) · Dermatitis (5) · Psoriasis (5) · Asthma (2) · Bronchiolitis Obliterans Syndrome (1) · Coinfection (1) · Facies (1) · Inflammation (1) · Lymphoma, Follicular (1) · Mandibulofacial Dysostosis (1) · Neurodermatitis (1) · Parasomnias (1) · Rhinitis, Allergic (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (100) · Genetic Diseases, Inborn (100) · Hypersensitivity (100) · Hypersensitivity, Immediate (100) · Immune System Diseases (100) · Skin Diseases (100) · Skin Diseases, Eczematous (100) · Skin Diseases, Genetic (100) · Skin and Connective Tissue Diseases (100) · Dermatitis (95) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (6) · Skin Manifestations (6) · Skin Diseases, Papulosquamous (5) · Bronchial Diseases (3)
dupilumab (20) · pimecrolimus (15) · crisaborole (8) · Cyclosporine (4) · abrocitinib (4) · lebrikizumab (4) · Omalizumab (3) · Tacrolimus (3) · ruxolitinib (3) · tralokinumab (3) · upadacitinib (3) · Adrenal Cortex Hormones (2) · Fluocinonide (2) · Fluticasone (2) · Hydrocortisone (2)
Novartis (8) · Sanofi (5) · University of California, San Francisco (5) · Wake Forest University Health Sciences (4) · Derm Research, PLLC (3) · Novartis Pharmaceuticals (3) · Technische Universität Dresden (3) · Wake Forest University (3) · Casa Espirita Terra de Ismael (2) · Ceragenix Pharmaceuticals (2) · Fougera Pharmaceuticals Inc. (2) · Innovaderm Research Inc. (2) · Instituto de Investigación Hospital Universitario La Paz (2) · Johns Hopkins University (2) · National Medical Research Center for Children's Health, Russian Federation (2)
United States (55) · Germany (9) · Canada (6) · Spain (6) · Switzerland (6) · United Kingdom (5) · Australia (4) · Brazil (4) · Netherlands (4) · China (3) · Italy (3) · Austria (2) · Belgium (2) · Denmark (2) · France (2)
Amy Paller, MD (2) · Fu-Tong Liu, M.D., Ph.D. (2) · Leon H. Kircik, M.D. (2) · Raymond Cho, MD, PhD (2) · Robert Bissonnette, MD (2) · Adelaide A Hebert, MD (1) · Alan Fleischer Jr., M.D. (1) · Alan Fleischer, MD (1) · Alberto M Borobia, MD, PhD (1) · Angela C Kaplan (1)
PMID 19403473, PMID 19863501, PMID 21099191, PMID 21533301, PMID 24435467, PMID 26598458, PMID 28330497, PMID 31764962, PMID 32212104, PMID 36806068, PMID 36824052, PMID 37181420, PMID 37429687, PMID 41350756, PMID 42027418, PMID 42126851
2018 (3), 2009 (1), 2023 (1)